The North America Stem Cell Manufacturing Market size was valued at USD 2,120 Million in 2025 and is expected to reach USD 6,430 Million by 2035, growing at a CAGR of 11.6% from 2024 to 2035.
The economic impact of tariffs on "North America Stem Cell Manufacturing Market".
Market Growth Drivers
Increasing investments in regenerative medicine and stem cell research have been a major growth driver in the North America Stem Cell Manufacturing Market. For example, Thermo Fisher Scientific has significantly expanded its cell therapy manufacturing infrastructure, focusing on scale-up technologies that promote end-to-end GMP-compliant solutions, particularly for stem cell-based therapeutics. This increased infrastructure and investment support a higher capacity and more reliable supply of clinical-grade stem cells, which boosts further research and commercialization opportunities.
Rising prevalence of chronic and degenerative diseases, such as diabetes, cardiovascular illnesses, and neurodegenerative disorders, stimulates demand for advanced treatment options, including stem cell therapies. Companies like Lonza Group have responded by increasing their manufacturing capabilities and partnering with biotech firms to provide CDMO (contract development and manufacturing organization) services, enabling faster development and commercialization of innovative stem cell therapies across the region.
Market Trends
Adoption of automated and scalable manufacturing technologies is a notable trend in the North America Stem Cell Manufacturing Market. Companies such as Becton Dickinson (BD Biosciences) are investing in cutting-edge automated bioreactor systems, eliminating manual processing variabilities and enabling consistent, large-scale, high-quality stem cell production. This trend not only increases product quality and safety but also addresses the demand for personalized medicine at a commercial scale.
Shift towards allogeneic stem cell therapies, which use donor cells rather than patient-derived cells, is accelerating market dynamics. Allogeneic manufacturing offers economies of scale and broader accessibility, as seen in BlueRock Therapeutics’ expansion into universal, off-the-shelf stem cell products. This approach addresses logistics, reduces wait times for patients, and enhances the potential for broader clinical adoption in North America.
Market Opportunity
Expanding collaborations between academic institutions, biotechnology firms, and government agencies represent a significant opportunity for the North America stem cell manufacturing market. For example, collaborations like that of GE Healthcare with the California Institute for Regenerative Medicine (CIRM) speed development and scaling of new therapies while navigating regulatory approval processes more efficiently.
The growing integration of artificial intelligence (AI) and analytics tools into cell manufacturing workflows offers a major opportunity to optimize quality control, predictive maintenance, and process automation. Companies such as Cytiva are developing AI-driven platforms for real-time process monitoring, enhancing operational efficiency and product consistency.
North America Stem Cell Manufacturing Market Revenue (2020-2035)
The line chart below illustrates the projected revenue growth of the North America Stem Cell Manufacturing Market from 2020 to 2035. The market, valued at USD 1,150 Million in 2020, demonstrated a strong upward trajectory, driven by advancements in manufacturing technologies and an expanding therapeutic pipeline. With compounded annual growth, the revenue is forecast to reach USD 2,120 Million by 2025 and further accelerate, hitting USD 6,430 Million by 2035. This sustained expansion highlights increasing adoption of cell therapies, expanding manufacturing collaboration, and regulatory advancements supporting commercialization across the region.
North America Stem Cell Manufacturing Market Regional Share (2025)
The pie chart demonstrates the regional distribution of the stem cell manufacturing market within North America for 2025. The United States dominates with a market share of 71%, owing to advanced infrastructure, heavy R&D funding, and a robust biotechnology sector. Canada holds a 17% share, driven by supportive government initiatives and increasing biotech investment. Mexico captures 6%, showing steady but emerging growth. The 'Rest of North America', including Caribbean territories, represents 4%. The Other/Undisclosed category accounts for the remaining 2%, encompassing collaborative multinational projects not assigned to a single country.
Recent Developments in North America Stem Cell Manufacturing Market (last 6 months)
In April 2024, Thermo Fisher Scientific launched a new state-of-the-art cell therapy manufacturing facility in Massachusetts, designed to provide GMP-grade stem cells for both clinical and commercial use. This move strengthens the company’s position as a leading contract development and manufacturing organization (CDMO) and expands stem cell supply capacity for North American and international pharmaceutical clients.
In March 2024, BlueRock Therapeutics, a Bayer company, received breakthrough FDA approval to proceed with Phase II trials for its proprietary allogeneic iPSC-derived cell therapy for Parkinson’s disease. This represents a major milestone, not only in clinical trial progression but also in large-scale manufacturing and regulatory streamlining for stem cell-based neurological therapies in the United States.
In February 2024, Lonza announced a strategic partnership with Canadian biotech firm Notch Therapeutics, focusing on the development and commercialization of scalable, off-the-shelf stem cell therapies. The partnership aims to leverage Lonza’s manufacturing expertise and Notch’s innovative platform to accelerate product launch timelines and address high demand for regenerative medicine solutions in North America.
Press Releases